Taiwan's Greenyn Biotechnology is working to get regulatory approvals in key Asia markets for Antrodia cinnamomea, after the so-called 'miracle mushroom' was found to improve the liver function of regular drinkers and chronic Hep B patients in trials funded by the firm.

牛樟芝為台灣原生種之紅色蕈類，許多醫學研究已證實，牛樟芝具有滋補強身，調整體質，健康維持等益處，素有「台灣國寶」之美譽。牛樟芝保健品市場活絡之時，其價格一度比金價還高，山老鼠竊取牛樟木事件層出不窮，而台灣各家業者也發展出多種培育方式以求永續。但因牛樟芝是台灣特有種，各國欠缺食用歷史，外銷叩關歐美各國始終遇到法規瓶頸，而如今，為各國法規圭臬的美國食品藥品監督管理局(FDA)甫公告一台灣業者之牛樟芝菌絲體於新膳食補充成份(New Dietary Ingredients, NDI)安全性評議回覆“無保留意見”，象徵著台灣之光已通過了國際安全性標準而可接軌國際。

Dietary supplements (e.g., vitamin, omega-3 fatty acid, herbs, etc.​) have recently drawn tremendous interests in combating COVID-19 around the globe.